Skip to main content
Erschienen in:

01.06.2006 | CME Weiterbildung • Zertifizierte Fortbildung

Neoadjuvante Chemotherapie von kolorektalen Lebermetastasen

verfasst von: Dr. G. Folprecht, C.-H. Köhne

Erschienen in: Die Onkologie | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Lebermetastasen können prinzipiell in kurativer Intention reseziert werden. Ist eine Resektion initial nicht möglich, kann sie bei einem Teil der Patienten nach einer neoadjuvanten Chemotherapie erfolgen. Das 5-Jahres-Überleben nach dieser Behandlung beträgt 33%. Da eine Tumorverkleinerung Bedingung für eine mögliche Resektion ist und die Resektionshäufigkeit mit der Ansprechrate korreliert, sollte ein Chemotherapieregime mit einer möglichst hohen Ansprechrate gewählt werden. Damit unterscheidet sich diese Behandlung von der palliativen Therapie des metastasierten kolorektalen Karzinoms. Sie erfordert eine intensive interdisziplinäre Zusammenarbeit. Hohe Ansprechraten werden durch die Kombination eines Antikörpers mit Irinotecan oder Oxaliplatin plus 5-FU-Infusion erreicht. Experimentell werden intensivere Kombinationsprotokolle untersucht. Mit Standardchemotherapien wie FOLFOX oder FOLFIRI wurden im Rahmen randomisierter Studien sekundäre Resektionsraten von 10% aller Patienten mit einem kolorektalen Karzinom erzielt; in den Studien zur neoadjuvanten Therapie lag dieser Wert bei etwa 30%.
Literatur
1.
Zurück zum Zitat Adam R, Pascal G, Castaing D et al. (2004) Tumor progression while on chemotherapy: a contradication to liver resection for multiple colorectal metastases? Ann Surg 240: 1052–1061CrossRefPubMed Adam R, Pascal G, Castaing D et al. (2004) Tumor progression while on chemotherapy: a contradication to liver resection for multiple colorectal metastases? Ann Surg 240: 1052–1061CrossRefPubMed
2.
Zurück zum Zitat Adam R, Delvart V, Pascal G et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644–657PubMed Adam R, Delvart V, Pascal G et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644–657PubMed
3.
Zurück zum Zitat Alberts SR, Horvath WL, Sternfeld WC et al. (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23: 9243–929CrossRefPubMed Alberts SR, Horvath WL, Sternfeld WC et al. (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23: 9243–929CrossRefPubMed
4.
Zurück zum Zitat Bismuth H, Adam R, Levi F et al. (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509–520CrossRefPubMed Bismuth H, Adam R, Levi F et al. (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509–520CrossRefPubMed
5.
Zurück zum Zitat Cals L, Rixe O, Francois E et al. (2004) Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 15: 1018–1024CrossRefPubMed Cals L, Rixe O, Francois E et al. (2004) Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 15: 1018–1024CrossRefPubMed
6.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345CrossRefPubMed Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345CrossRefPubMed
7.
Zurück zum Zitat De La Camara J, Rodriguez J, Rotellar F et al. (2004) Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer (Abstract 3593). J Clin Oncol [Suppl 14] 22: 3593 De La Camara J, Rodriguez J, Rotellar F et al. (2004) Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer (Abstract 3593). J Clin Oncol [Suppl 14] 22: 3593
8.
Zurück zum Zitat Diaz-Rubio E, Tabernero J, Van Cutsem E et al. (2005) Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study (Abstract 3535). ASCO Annual Meeting, Orlando, FL Diaz-Rubio E, Tabernero J, Van Cutsem E et al. (2005) Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study (Abstract 3535). ASCO Annual Meeting, Orlando, FL
9.
Zurück zum Zitat Falcone A, Masi G, Murr R et al. (2006) Biweekly irinotecan, oxaliplatin, and infusional 5FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (GONO) (Abstract 227). Gastrointestinal Cancers Symposium, San Francisco, CA Falcone A, Masi G, Murr R et al. (2006) Biweekly irinotecan, oxaliplatin, and infusional 5FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (GONO) (Abstract 227). Gastrointestinal Cancers Symposium, San Francisco, CA
10.
Zurück zum Zitat Figueras J, Valls C, Rafecas A et al. (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88: 980–985CrossRefPubMed Figueras J, Valls C, Rafecas A et al. (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88: 980–985CrossRefPubMed
11.
Zurück zum Zitat Folprecht G, Grothey A, Alberts S et al. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311–1319CrossRefPubMed Folprecht G, Grothey A, Alberts S et al. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311–1319CrossRefPubMed
12.
Zurück zum Zitat Folprecht G, Lutz M, Schöffski P et al. (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450–456CrossRefPubMed Folprecht G, Lutz M, Schöffski P et al. (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17: 450–456CrossRefPubMed
13.
Zurück zum Zitat Fong Y, Fortner J, Sun RL et al. (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309–318CrossRefPubMed Fong Y, Fortner J, Sun RL et al. (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309–318CrossRefPubMed
14.
Zurück zum Zitat Fowler WC, Eisenberg BL, Hoffman JP (1992) Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 51: 122–125PubMed Fowler WC, Eisenberg BL, Hoffman JP (1992) Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 51: 122–125PubMed
15.
Zurück zum Zitat Giacchetti S, Itzhaki M, Gruia G et al. (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10: 663–669CrossRefPubMed Giacchetti S, Itzhaki M, Gruia G et al. (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10: 663–669CrossRefPubMed
16.
Zurück zum Zitat Grothey A, Deschler B, Kroening H et al. (2001) Bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high dose 24H 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC). Results of a phase III study. ASCO Annual Meeting, San Francisco, CA Grothey A, Deschler B, Kroening H et al. (2001) Bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high dose 24H 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (CRC). Results of a phase III study. ASCO Annual Meeting, San Francisco, CA
17.
Zurück zum Zitat Gruenberger T, Schuell B, Kornek G et al. (2004) Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: impact on magnitude of liver resection and survival (Abstract 3598). ASCO Annual Meeting, New Orleans Gruenberger T, Schuell B, Kornek G et al. (2004) Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: impact on magnitude of liver resection and survival (Abstract 3598). ASCO Annual Meeting, New Orleans
18.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342CrossRefPubMed Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342CrossRefPubMed
19.
Zurück zum Zitat Köhne CH, Cunningham D, Di Costanzo F et al. (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308–317CrossRefPubMed Köhne CH, Cunningham D, Di Costanzo F et al. (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308–317CrossRefPubMed
20.
Zurück zum Zitat Köhne CH, Van Cutsem E, Wils J et al. (2005) Phase III study of weekly high-dose infusional 5-fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer. EORTC Gastrointestinal Group Study 40986. J Clin Oncol 23: 4856–4865CrossRefPubMed Köhne CH, Van Cutsem E, Wils J et al. (2005) Phase III study of weekly high-dose infusional 5-fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer. EORTC Gastrointestinal Group Study 40986. J Clin Oncol 23: 4856–4865CrossRefPubMed
21.
Zurück zum Zitat Nordlinger B, Guiguet M, Vaillant JC et al. (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77: 1254–1262CrossRefPubMed Nordlinger B, Guiguet M, Vaillant JC et al. (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77: 1254–1262CrossRefPubMed
22.
Zurück zum Zitat Pozzo C, Basso M, Cassano A et al. (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15: 933–939CrossRefPubMed Pozzo C, Basso M, Cassano A et al. (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15: 933–939CrossRefPubMed
23.
Zurück zum Zitat Quenet F, Nordlinger B, Rivoire M et al. (2004) Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial (Abstract 3613). ASCO Annual Meeting, New Orleans Quenet F, Nordlinger B, Rivoire M et al. (2004) Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): a prospective phase II trial (Abstract 3613). ASCO Annual Meeting, New Orleans
24.
Zurück zum Zitat Rivoire M, De Cian F, Meeus P et al. (2002) Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95: 2283–2292CrossRefPubMed Rivoire M, De Cian F, Meeus P et al. (2002) Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 95: 2283–2292CrossRefPubMed
25.
Zurück zum Zitat Rubbia-Brandt L, Audard V, Sartoretti P et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460–466CrossRefPubMed Rubbia-Brandt L, Audard V, Sartoretti P et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460–466CrossRefPubMed
26.
Zurück zum Zitat Scappaticci F, Fehrenbacher L, Cartwright T et al. (2004) Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab (Abstract 235). Gastrointestinal Cancers Symposium, San Francisco, CA Scappaticci F, Fehrenbacher L, Cartwright T et al. (2004) Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab (Abstract 235). Gastrointestinal Cancers Symposium, San Francisco, CA
27.
Zurück zum Zitat Scheele J, Stang R, Altendorf Hofmann A et al. (1995) Resection of colorectal liver metastases. World J Surg 19: 59–71CrossRefPubMed Scheele J, Stang R, Altendorf Hofmann A et al. (1995) Resection of colorectal liver metastases. World J Surg 19: 59–71CrossRefPubMed
28.
Zurück zum Zitat Seium Y, Stupp R, Ruhstaller T et al. (2005) Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study. Ann Oncol 16: 762–766CrossRefPubMed Seium Y, Stupp R, Ruhstaller T et al. (2005) Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I–II study. Ann Oncol 16: 762–766CrossRefPubMed
29.
Zurück zum Zitat Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321: 531–535CrossRefPubMed Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321: 531–535CrossRefPubMed
30.
Zurück zum Zitat Souglakos J, Androulakis N, Syrigos K et al. (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798–805CrossRefPubMed Souglakos J, Androulakis N, Syrigos K et al. (2006) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798–805CrossRefPubMed
31.
Zurück zum Zitat Tournigand C, Andre T, Achille E et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22: 229–237CrossRefPubMed Tournigand C, Andre T, Achille E et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22: 229–237CrossRefPubMed
32.
Zurück zum Zitat Zelek L, Bugat R, Cherqui D et al. (2003) Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 14: 1537–1542CrossRefPubMed Zelek L, Bugat R, Cherqui D et al. (2003) Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 14: 1537–1542CrossRefPubMed
Metadaten
Titel
Neoadjuvante Chemotherapie von kolorektalen Lebermetastasen
verfasst von
Dr. G. Folprecht
C.-H. Köhne
Publikationsdatum
01.06.2006
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 6/2006
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1069-8

Weitere Artikel der Ausgabe 6/2006

Der Onkologe 6/2006 Zur Ausgabe

Onkologie im Internet

Webadressen zu Hirntumoren

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.